Havana, 25 nov (EFE).-United Kingdom apply in the coming weeks a clinical trial of a therapeutic vaccine against lung cancer advanced, CIMAvax-EGF, created by scientists from the center of Molecular Immunology of Havana in Cuba, today confirmed to Efe sources.

The study has been approved by the regulatory agency of United Kingdom after the recent authorization of a multinational, multicenter clinical trial for vaccine Protocol, according to a source of the marketer CIMAB S.A., exclusive representative of the center of Molecular Immunology (CIM) reported today to Efe.

According to the source, in a week or two will be included the first British patient in study

It is also expected next clinical trials in countries such as Australia, Thailand and Malaysia.

Cuban medicine was developed after 15 years of research by scientists at the CIM, who believe that the same principle of the drug could be used in the treatment of oncological illnesses.

According to Cuban experts the drug may not prevent disease but allows you to control advanced cancer to generate antibodies against proteins that trigger the slippage in the processes of proliferation cell.

Membership includes protein P-64 K of the membrane and epidermal growth factor, obtained through recombinant.

With the name commercial CIMAVAX-EGF, the vaccine has been applied with good results to more than 1,000 patients in Cuba, where su record health was conducted in June 2008.

The product was also already registered in Peru and is in the process of registration in other countries of the region, such as Colombia, Brazil, Paraguay, Ecuador and Argentina.

The Director of the project, Gisela Gonzalez, said last January that the vaccine is safe, does not cause severe effects and increases the life expectancy of the patient, with a good quality.

Cuban media have stressed that CIMAVAX-EGF is the first therapeutic vaccine against cancer lung progress registered in the world.

According to data from the World Health Organization, cancer is the leading cause of mortality worldwide, and the lung is one of the of greatest incidence.

It is estimated that in 2008 cancer 7.6 million people died, figure that will rise up to eleven million in 2030. EFE